Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
101-PGC-005 vs Dexamethasone in Moderate COVID-19
NCT05656521Phase 2Unknown
- Sponsor
- 101 Therapeutics
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 101-PGC-005 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by 101 Therapeutics. Primary endpoint: Clinical Improvement at Day 28. Status: unknown.
02
Drugs
101-PGC-005
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05656521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656521.